<DOC>
	<DOCNO>NCT02879617</DOCNO>
	<brief_summary>This single-arm phase II clinical trial evaluate safety efficacy PD-L1 inhibitor durvalumab first-line therapy 50 patient advanced NSCLC ECOG Performance Status 2 ( PS2 ) .</brief_summary>
	<brief_title>A Clinical Trial Durvalumab ( MEDI4736 ) 1st Line Therapy Advanced Non-small Cell Lung Cancer Patients</brief_title>
	<detailed_description>Durvalumab supply glass vial contain 500 mg liquid solution concentration 50 mg/mL intravenous ( IV ) administration . Durvalumab administer 1500 mg ( fix dose ) every 4 week disease progression , death , unacceptable toxicity withdrawal consent maximum 12 month therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent Patients must histologically cytologically confirm Stage IIIB IV ( American Joint Committee Cancer , 7th edition ; AJCC 7 ) nonsmall cell lung cancer . Patients must measurable disease . Patients must receive prior therapy ( chemotherapy , immunotherapy , endocrine therapy , target therapy , biologic therapy , tumor embolization , monoclonal antibody , investigational agent ) treatment stage IV NSCLC . Age ≥ 18 year time study entry . ECOG performance status 2 . Life expectancy great 12 week . Tissue available ( archive fresh tumor biopsy ) PDL1 assay . Patients must normal organ marrow function define : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ( &gt; 1500 per mm^3 ) Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100 x 10^9/L ( &gt; 100,000 per mm^3 ) Serum bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) . AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x ULN unless liver metastasis present , case must ≤ 5x ULN Serum creatinine CL &gt; 40 mL/min CockcroftGault formula Female subject must either nonreproductive potential OR must negative serum pregnancy test upon study entry . The effect durvalumab develop human fetus unknown . For reason immunomodulatory agent potentially teratogenic , sexually active woman childbearing potential men must agree use adequate contraception ( 2 method effective contraception screen ) screening , duration study participation , least 90 day follow last infusion durvalumab . Subject willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . Involvement plan and/or conduct study ; previous enrollment present study . Participation another clinical study investigational product cancer last 12 month . Any previous treatment PD1 PDL1 inhibitor , include durvalumab . Symptomatic uncontrolled brain metastasis require concurrent treatment , inclusive limited surgery , radiation and/or corticosteroid . Sensitizing mutation EGFR rearrangement ALK ROS1 . History allergic reaction attribute compound similar chemical biologic composition durvalumab . Mean QT interval correct heart rate ( QTc ) ≥ 470 ms. Current prior use immunosuppressive medication within 28 day first dose durvalumab . Active prior document autoimmune disease within past 2 year NOTE : Subjects vitiligo , Grave 's disease , psoriasis require systemic treatment ( within past 2 year ) exclude . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) . History primary immunodeficiency . History allogeneic organ transplant . Uncontrolled intercurrent illness . Known history previous clinical diagnosis tuberculosis . History leptomeningeal carcinomatosis . Receipt live attenuate vaccination within 30 day prior study entry within 30 day receive durvalumab . Any condition , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result . Subjects uncontrolled seizure . Pregnant woman ; breastfeed discontinue . Prior history radiation pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>